
    
      This trial will:

        1. Determine the proportion of patients in which treatment with the study drug results in
           an increase in total hemoglobin by 1.5 g/dl above baseline levels when administered for
           26 weeks in Thai patients with beta thalassemia intermedia, including Hemoglobin E beta
           thalassemia.

        2. Determine the number and proportion of participants in whom treatment with the study
           drug results in an increase in fetal hemoglobin.

        3. Determine the number of participants who have adverse events.
    
  